Comparing different preparations and doses of rosehip powder in patients with osteoarthritis of the knee: An exploratory randomized active-controlled trial

Robin Christensen, Simon Tarp, Roy D. Altman, Marius Henriksen, Else M. Bartels, Louise Klokker, Mikael Boesen, Daniel E. Furst, Christian C. Holm, Bente Danneskiold-Samsøe, Henning Bliddal

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Aim: We compared original rosehip powder consisting of whole rosehips including seeds, with two different doses of a novel enhanced rosehip powder of rosehips without their seeds, for patients with knee osteoarthritis (OA). Methods: A total of 150 patients with symptomatic knee OA were randomly assigned to original powder (six capsules/day), enhanced powder (six capsules/day) or enhanced powder (three capsules/day). The primary outcome was change from baseline in the Knee Injury and Osteoarthritis Outcome Score (KOOS) item, 'pain during walking on flat surface, assessed after 12 weeks. Statistical analyses were based on the intention-to-treat population. Results: During the trial period the change in the primary outcome was comparable across groups. Changes in the KOOS symptoms supported a potential superiority of enhanced powder versus original powder, with a difference of 5.97 KOOS points (95% CI: 0.92-11.02; p = 0.02). Conclusion: Enhanced rosehip powder is at least as good, even taken as three capsules/day, as the original rosehip product for patients with symptomatic OA.

Original languageEnglish (US)
Pages (from-to)267-278
Number of pages12
JournalInternational Journal of Clinical Rheumatology
Volume9
Issue number3
DOIs
StatePublished - Jun 2014

Keywords

  • dietary supplements
  • knee
  • osteoarthritis
  • pain
  • randomized controlled trial
  • rosehips

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Comparing different preparations and doses of rosehip powder in patients with osteoarthritis of the knee: An exploratory randomized active-controlled trial'. Together they form a unique fingerprint.

Cite this